ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsang, K.
Right arrow Articles by Ip, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsang, K.
Right arrow Articles by Ip, M.
Eur Respir J 1999; 14: 1206-1209
Copyright © ERS Journals Ltd 1999


Clinical Trial

A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis

KW Tsang, WM Chan, PL Ho, K Chan, WK Lam, and MS Ip

A prospective randomized study was performed in order to compare the efficacy of oral levofloxacin, a new S- isomer of ofloxacin, with intravenous ceftazidime in the empirical treatment of acute exacerbations of bronchiectasis. Consecutive patients with acute exacerbation of bronchiectasis were recruited at a tertiary referral centre and were randomized to receive 10 days' treatment with either oral levofloxacin (300 mg b..d.) or ceftazidime (1 g i.v.t.d.). Body temperature, cough score, dyspnoea score, sputum purulence and volume and white blood cell and neutrophil count were assessed on day 1 and day 10. Thirty-five patients (mean age 61 yrs, 15 males) completed the study; 17 of these were in the levofloxacin group. There was no significant difference in the distribution of sputum pathogens or clinical parameters between the two groups at entry to and completion of the study. Both groups of patients showed significant improvement in 24-h sputum volume, sputum purulence score, cough score and dyspnoea score (p<0.001) but there was no significant difference between these two groups at entry to or on completion of the study (p>0.05). The results of this study suggest that oral administration of levofloxacin is as effective as parenteral ceftazidime in the empirical treatment of exacerbations in bronchiectasis.


This article has been cited by other articles:


Home page
ChestHome page
A. E. O'Donnell
Bronchiectasis
Chest, October 1, 2008; 134(4): 815 - 823.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Bilton, N. Henig, B. Morrissey, and M. Gotfried
Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis.
Chest, November 1, 2006; 130(5): 1503 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij
Guidelines for the management of adult lower respiratory tract infections
Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. F. Barker
Bronchiectasis
N. Engl. J. Med., May 2, 2002; 346(18): 1383 - 1393.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.